AlphAIAlphAI — Financial news for AI agents
finance.yahoo.com$OSUR

OraSure Technologies Q3 Earnings Call Highlights

OraSure (NASDAQ:OSUR) reported a Q3 GAAP operating loss of $13M and non-GAAP loss of $10.2M. It forecasts Q4 revenue of $30M-$32M, up 12-20% YoY. The company expects full-year revenue growth to accelerate in 2027. OraSure has launched its Ebola 2.0 rapid antigen test and Colli-Pee Dx urine collection kit, with initial sales encouraging. It is working on FDA pre-submission for its InteliQuick CT/NG molecular self-test.

Original reporting
finance.yahoo.com
Published Nov 10, 2026, 1:14 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 10, 2026, 1:26 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
OraSure Technologies Q3 Earnings Call Highlights — source image
Source · finance.yahoo.com
Decision brief

The 30-second read

$OSURBearishMed
01

Why it matters

The guidance downgrade and loss suggest near‑term earnings weakness, but the company’s cash reserves and new product launches may support longer‑term growth.

02

Market read

Investors will reassess OSUR valuation based on the loss and lowered guidance, potentially prompting a short‑term price decline.

03

What to watch

Strong cash position ($148M) and no debt provide runway for strategic investments despite current guidance.

Relevance 7/10Novelty 7/10Timing: after-hours reaction

Background

OraSure Technologies (NASDAQ:OSUR) provides rapid diagnostic tests and specimen‑collection kits. The Q3 call highlighted operating losses, cash burn, and revised guidance.

Company-level read

Ticker impact

$OSURBearishHigh confidence
Context

Q3 earnings disclosed a GAAP operating loss of $13M and lowered Q4 revenue guidance to $30‑32M, indicating weaker near‑term performance.

Expected impact

likely downside pressure as investors price in weaker guidance and cash burn

Evidence & confidence

The company posted a loss and reduced its revenue outlook, which typically triggers sell‑side reactions in the short term.

Market effects

Sector

Diagnostic and point‑of‑care testing sector may see heightened scrutiny on revenue forecasts.

Regional

Limited to U.S. biotech/health‑care investors.

Global

Minimal; impact confined to OraSure and its immediate peers.

Counterpoint

What could challenge this read

The Ebola test and new urine kit could unlock sizable contracts in emerging markets, offsetting short‑term losses.

Key entities

  • Executive
    Carrie Eglinton Manner

    President and CEO of OraSure, provided commentary on product pipeline and guidance.

Read at source← All news

Also covered by

1 outlet

Related articles

$OSURMed

OraSure: Q3 Earnings Snapshot

OraSure Technologies (OSUR) reported a Q3 loss of $13.1M, or 19 cents per share. Adjusted losses were 15 cents per share. Revenue was $30.9M. The company expects Q4 revenue between $30M and $32M.

finance.yahoo.com
$OSURMed

OraSure Announces Third Quarter 2026 Financial Results; Strategic Execution Drives Double-Digit Year-Over-Year Growth and Margin Expansion

ORASURE TECHNOLOGIES INC (OSUR) filed an SEC Form 8-K — Results of Operations and Financial Condition. EXHIBIT 99.1 Investor Contact: Media Contact: Mike Vallie Amy Koch investorinfo@orasure.com media@orasure.com OraSure Announces Third Quarter 2026 Financial Results; Strategic Execution Drives Double-Digit Year-Over-Year Growth and Margin Expansion • 14% year-over-year revenue gr

SEC EDGAR 8-K
$OSURMed

OraSure (OSUR) Returns To Profit, But Growth Remains Elusive

OraSure (OSUR) reported Q2 2026 GAAP net income of $6.2M, reversing a $19.7M loss from a year earlier. Revenue rose 9.7% quarter-over-quarter to $30.6M, beating guidance. Gross margins improved, and diagnostics revenue grew 1% YoY. The profit was largely due to a $22.6M accounting adjustment, with underlying losses widening. The company secured two FDA clearances but delayed a product submission. Hedge fund ownership increased, and short interest is 4.79%.

insidermonkey.com
$OSURMedAI 8/10

OraSure (OSUR) Q2 2026 Earnings Call Transcript

OraSure Technologies (OSUR) reported Q2 2026 revenue of $30.6M, up 9.7% sequentially, including $19.4M Diagnostics revenue and $9.9M Sample Management Solutions revenue. GAAP gross margin was 43.5% and GAAP operating income $5.4M. Q3 revenue guidance is $29.5M to $32.5M. Management said FDA clearance for Colli-Pee and EUA for OraQuick Ebola 2.0 were received, while IntelliQ CT/NG submission was withdrawn.

fool.com
$OSURMed

OraSure Announces Second Quarter 2026 Financial Results

ORASURE TECHNOLOGIES INC (OSUR) filed an SEC Form 8-K — Results of Operations and Financial Condition. EXHIBIT 99.1 Investor Contact: Media Contact: investorinfo@orasure.com media@orasure.com OraSure Announces Second Quarter 2026 Financial Results BETHLEHEM, PA, August 5, 2026 (GLOBE NEWSWIRE) – OraSure Technologies, Inc. (Nasdaq: OSUR), a leader in point-of-need and home diagnost

SEC EDGAR 8-K
$OSURMedAI 8/10

OraSure receives Emergency Use Authorization for second generation Ebola test

OraSure Technologies said the U.S. FDA granted Emergency Use Authorization for its second generation OraQuick Ebola 2.0 Rapid Antigen Test. The single-use test detects four Ebola virus types and can use blood or oral fluids. OraSure cited improved sensitivity, longer shelf life, and automated manufacturing, and plans to ramp production. The DRC and Uganda outbreak has 2,473 cases and 999 deaths, per Congo’s Ministry of Health.

wfmz.com